Intensity Therapeutics, Inc.
INTS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,553 | $1,541 | $2,189 | $1,967 |
| G&A Expenses | $1,180 | $1,164 | $1,205 | $1,236 |
| SG&A Expenses | $1,180 | $1,164 | $1,205 | $1,236 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,733 | $2,705 | $3,394 | $3,203 |
| Operating Income | -$2,733 | -$2,705 | -$3,394 | -$3,203 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $62 | $168 | $47 | $22 |
| Pre-Tax Income | -$2,671 | -$2,537 | -$3,347 | -$3,181 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,671 | -$2,537 | -$3,347 | -$3,181 |
| % Margin | – | – | – | – |
| EPS | -0.06 | -0.13 | -0.22 | -0.22 |
| % Growth | 53.8% | 40.9% | 0% | – |
| EPS Diluted | -0.06 | -0.13 | -0.22 | -0.22 |
| Weighted Avg Shares Out | 18,868 | 18,868 | 15,173 | 14,628 |
| Weighted Avg Shares Out Dil | 18,868 | 18,868 | 15,173 | 14,628 |
| Supplemental Information | – | – | – | – |
| Interest Income | $59 | $17 | $15 | $28 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,733 | $0 | $0 | $0 |
| EBITDA | $62 | -$2,705 | -$3,394 | -$3,181 |
| % Margin | – | – | – | – |